Disease relevance of Defibrillators, Implantable

• Although beta-blockers, angiotensin-converting enzyme inhibitors, and revascularization play a role in prevention of sudden cardiac death, the development and subsequent refinement of the implantable cardioverter-defibrillator has made the most important contribution to its management [1].
• BACKGROUND: The Antiarrhythmics Versus Implantable Defibrillators (AVID) Study compared treatment with implantable cardioverter-defibrillators versus antiarrhythmic drugs in patients with life-threatening ventricular arrhythmias (VAs) [2].
• Morning peak in ventricular tachyarrhythmias detected by time of implantable cardioverter/defibrillator therapy. The CPI Investigators [3].
• Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease [4].
• Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator [5].

High impact information on Defibrillators, Implantable

• Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy [6].
• Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group [7].
• Overall, 227 patients (45%) were discharged on conventional antiarrhythmic agents, 115 (23%) on amiodarone, 39 (8%) received an implantable defibrillator, and 120 (24%) received no specific antiarrhythmic therapy [8].
• Driving and the implantable cardioverter defibrillator. Study Group on ICD and Driving [9].
• METHODS AND RESULTS: Screening for the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial identified patients with both stable and unstable VT [10].

Chemical compound and disease context of Defibrillators, Implantable

• OBJECTIVES: The purpose of this multicenter randomized trial was to compare total mortality during therapy with amiodarone or an implantable cardioverter-defibrillator (ICD) in patients with nonischemic dilated cardiomyopathy (NIDCM) and nonsustained ventricular tachycardia (NSVT) [11].
• Concomitant use of propafenone in patients with implantable cardioverter-defibrillators with recurrent ventricular or atrial tachyarrhythmias should not interfere with proper device function [12].
• Cardiac release of histamine after ventricular fibrillation and defibrillation during insertion of implantable cardioverter defibrillators (ICD) [13].
• Serum creatine kinase activity and sensing characteristics after intraoperative arrhythmia induction using implantable defibrillator rate sensing leads [14].
• Since these patients are at risk of sudden cardiac death from birth, and implantable cardioverter-defibrillator implantation has a lot of limitations in very young children, the utility of quinidine has to be evaluated further [15].

Biological context of Defibrillators, Implantable

• Survival analysis and clinical medicine. An observational comparison of the implantable cardioverter defibrillator, amiodarone treatment, and heart transplantation [16].
• Fractal correlation properties of heart rate dynamics and adverse events in patients with implantable cardioverter-defibrillators [17].
• Finally, in patients with chronic dilated non-ischemic cardiomyopathy and a left ventricular ejection fraction of 0.35 or below, there is also benefit from prophylactic implantable cardioverter defibrillator therapy [18].
• Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function [19].

Anatomical context of Defibrillators, Implantable

• We describe a case that illustrates the complementary physiologic role of indium-111-labeled leukocyte scintigraphy in identifying and defining the extent of early postoperative implantable cardioverter-defibrillator infection [20].
• Concomitant cardiac procedures included mitral valve repair (n = 2), automatic implantable cardioverter defibrillator implantation (n = 1), and closure of atrial septal defect (n = 1) [21].

Associations of Defibrillators, Implantable with chemical compounds

• In a canine model, procainamide (PA) was delivered iontophoretically using pulsed current synchronized with the ventricular depolarization via an implantable defibrillator patch electrode that was modified to contain a 3.6-ml chamber [22].
• Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators [12].
• OBJECTIVES: This study evaluated the effects of azimilide dihydrochloride (AZ) on anti-tachycardia pacing (ATP) and shock-terminated events in patients with implantable cardioverter defibrillators (ICDs) [23].
• Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigators Group [24].
• METHODS: Forty-nine consecutive patients with an indication for anticoagulation with heparin after implantable defibrillator or pacemaker implantation were randomized to receive intravenous heparin either 6 h (n = 26) or 24 h (n = 23) postoperatively [25].

Gene context of Defibrillators, Implantable

• Mutations of the cardiac sodium channel SCN5A cause the disorder, and an implantable cardioverter-defibrillator is often recommended for affected individuals [26].
• The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5) [27].
• LQT III and Brugada syndromes have a high case fatality rate and are best treated with an implantable defibrillator [28].
• INTRODUCTION: Discrimination of ventricular and supraventricular arrhythmias remains one of the major challenges for appropriate implantable defibrillator (ICD) therapy delivery [29].
• Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy [30].

Analytical, diagnostic and therapeutic context of Defibrillators, Implantable

• Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators [31].
• Sometimes, relatively small trials, such as the Multicenter Automatic Defibrillator Implantation Trial and the Antiarrhythmics Versus Implantable Defibrillators study, may be taken as guides for current clinical decisions and as inspiration for future investigations [32].
• This may have important clinical implications in patients with automatic implantable cardioverter-defibrillators (AICDs) receiving concomitant antiarrhythmic drug therapy and in patients undergoing therapy with intravenous propafenone [33].
• Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial). Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation [34].
• Therapy guided by programmed electrical stimulation or Holter monitoring is likely to play a diminishing role in the development of antiarrhythmic drug regimens, and thus an antiarrhythmic agent's effectiveness may need to be evaluated against the background of implantable cardioverter-defibrillators or against amiodarone therapy [35].

References